Antibiotic treatment of Mycobacterium abscessus lung disease: A retrospective analysis of 65 patients

Kyeongman Jeon, O. Jung Kwon, Yong Lee Nam, Bum Joon Kim, Yoon Hoh Kook, Seung Heon Lee, Kil Park Young, Ki Kim Chang, Won Jung Koh

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess the efficacy of a standardized combination antibiotic therapy for the treatment of M. abscessus lung disease. Methods: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization. Measurements and Main Results: Treatment response rates were 83% for symptoms and 74% for high-resolution computed tomography. Sputum conversion and maintenance of negative sputum cultures for more than 12 months was achieved in 38 (58%) patients. These rates were significantly lower in patients whose isolates were resistant to clarithromycin (17%, 2/12) compared with those whose isolates were susceptible or intermediate to clarithromycin (64%, 21/33; P = 0.007). Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively. Drug-induced hepatotoxicity occurred in 10 (15%) patients. Because of these adverse reactions, cefoxitin was discontinued in 39 (60%) patients after treatment for a median of 22 days. Conclusions: Standardized combination antibiotic therapy was moderately effective in treating M. abscessus lung disease. However, frequent adverse reactions and the potential for long-duration hospitalization are important problems that remain to be solved.

Original languageEnglish
Pages (from-to)896-902
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume180
Issue number9
DOIs
Publication statusPublished - 2009 Nov 1
Externally publishedYes

Fingerprint

Mycobacterium
Lung Diseases
Anti-Bacterial Agents
Cefoxitin
Clarithromycin
Sputum
Therapeutics
Hospitalization
Amikacin
Doxycycline
Ciprofloxacin
Neutropenia
Thrombocytopenia
Tomography
Maintenance
Pharmaceutical Preparations

Keywords

  • Atypical mycobacteria
  • Lung diseases
  • Mycobacterium abscessus
  • Treatment outcome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Antibiotic treatment of Mycobacterium abscessus lung disease : A retrospective analysis of 65 patients. / Jeon, Kyeongman; Kwon, O. Jung; Nam, Yong Lee; Kim, Bum Joon; Kook, Yoon Hoh; Lee, Seung Heon; Young, Kil Park; Chang, Ki Kim; Koh, Won Jung.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 180, No. 9, 01.11.2009, p. 896-902.

Research output: Contribution to journalArticle

Jeon, Kyeongman ; Kwon, O. Jung ; Nam, Yong Lee ; Kim, Bum Joon ; Kook, Yoon Hoh ; Lee, Seung Heon ; Young, Kil Park ; Chang, Ki Kim ; Koh, Won Jung. / Antibiotic treatment of Mycobacterium abscessus lung disease : A retrospective analysis of 65 patients. In: American Journal of Respiratory and Critical Care Medicine. 2009 ; Vol. 180, No. 9. pp. 896-902.
@article{55996ba449a744fba7a01e954f4cbf11,
title = "Antibiotic treatment of Mycobacterium abscessus lung disease: A retrospective analysis of 65 patients",
abstract = "Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess the efficacy of a standardized combination antibiotic therapy for the treatment of M. abscessus lung disease. Methods: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization. Measurements and Main Results: Treatment response rates were 83{\%} for symptoms and 74{\%} for high-resolution computed tomography. Sputum conversion and maintenance of negative sputum cultures for more than 12 months was achieved in 38 (58{\%}) patients. These rates were significantly lower in patients whose isolates were resistant to clarithromycin (17{\%}, 2/12) compared with those whose isolates were susceptible or intermediate to clarithromycin (64{\%}, 21/33; P = 0.007). Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51{\%}) and 4 (6{\%}) patients, respectively. Drug-induced hepatotoxicity occurred in 10 (15{\%}) patients. Because of these adverse reactions, cefoxitin was discontinued in 39 (60{\%}) patients after treatment for a median of 22 days. Conclusions: Standardized combination antibiotic therapy was moderately effective in treating M. abscessus lung disease. However, frequent adverse reactions and the potential for long-duration hospitalization are important problems that remain to be solved.",
keywords = "Atypical mycobacteria, Lung diseases, Mycobacterium abscessus, Treatment outcome",
author = "Kyeongman Jeon and Kwon, {O. Jung} and Nam, {Yong Lee} and Kim, {Bum Joon} and Kook, {Yoon Hoh} and Lee, {Seung Heon} and Young, {Kil Park} and Chang, {Ki Kim} and Koh, {Won Jung}",
year = "2009",
month = "11",
day = "1",
doi = "10.1164/rccm.200905-0704OC",
language = "English",
volume = "180",
pages = "896--902",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Antibiotic treatment of Mycobacterium abscessus lung disease

T2 - A retrospective analysis of 65 patients

AU - Jeon, Kyeongman

AU - Kwon, O. Jung

AU - Nam, Yong Lee

AU - Kim, Bum Joon

AU - Kook, Yoon Hoh

AU - Lee, Seung Heon

AU - Young, Kil Park

AU - Chang, Ki Kim

AU - Koh, Won Jung

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess the efficacy of a standardized combination antibiotic therapy for the treatment of M. abscessus lung disease. Methods: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization. Measurements and Main Results: Treatment response rates were 83% for symptoms and 74% for high-resolution computed tomography. Sputum conversion and maintenance of negative sputum cultures for more than 12 months was achieved in 38 (58%) patients. These rates were significantly lower in patients whose isolates were resistant to clarithromycin (17%, 2/12) compared with those whose isolates were susceptible or intermediate to clarithromycin (64%, 21/33; P = 0.007). Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively. Drug-induced hepatotoxicity occurred in 10 (15%) patients. Because of these adverse reactions, cefoxitin was discontinued in 39 (60%) patients after treatment for a median of 22 days. Conclusions: Standardized combination antibiotic therapy was moderately effective in treating M. abscessus lung disease. However, frequent adverse reactions and the potential for long-duration hospitalization are important problems that remain to be solved.

AB - Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess the efficacy of a standardized combination antibiotic therapy for the treatment of M. abscessus lung disease. Methods: Sixty-five patients (11 males, 55 females, median age 55 yr) with M. abscessus lung disease were treated with clarithromycin, ciprofloxacin, and doxycycline, together with an initial regimen of amikacin and cefoxitin for the first 4 weeks of hospitalization. Measurements and Main Results: Treatment response rates were 83% for symptoms and 74% for high-resolution computed tomography. Sputum conversion and maintenance of negative sputum cultures for more than 12 months was achieved in 38 (58%) patients. These rates were significantly lower in patients whose isolates were resistant to clarithromycin (17%, 2/12) compared with those whose isolates were susceptible or intermediate to clarithromycin (64%, 21/33; P = 0.007). Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively. Drug-induced hepatotoxicity occurred in 10 (15%) patients. Because of these adverse reactions, cefoxitin was discontinued in 39 (60%) patients after treatment for a median of 22 days. Conclusions: Standardized combination antibiotic therapy was moderately effective in treating M. abscessus lung disease. However, frequent adverse reactions and the potential for long-duration hospitalization are important problems that remain to be solved.

KW - Atypical mycobacteria

KW - Lung diseases

KW - Mycobacterium abscessus

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=70350432979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350432979&partnerID=8YFLogxK

U2 - 10.1164/rccm.200905-0704OC

DO - 10.1164/rccm.200905-0704OC

M3 - Article

C2 - 19661243

AN - SCOPUS:70350432979

VL - 180

SP - 896

EP - 902

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -